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Abstract  Article Info 
Introduction: Nasopharyngeal Carcinoma (NPC) is a squamous cell malignant tumor that usually occurs 
in the lateral wall of the nasopharynx near the area of the eustachian tube. NPC is often found in southern 
Asia. In head and neck areas, NPC is one of the top five malignant which has the highest frequency 
tumours in Indonesia.  
Case report: We reported a case of a 57-year-old man with complaints of obstruction in both noses, 
accompanied by headache. Based on medical history, physical and Radiology examination, we concluded 
that he was diagnosed with Nasopharyngeal Carcinoma WHO II Stage III (T3N0M0). Histopathology 
revealed a differentiated non keratinizing squamous cell carcinoma in the nasopharynx. Six cycles of 
carboplatin and docetaxel regimen as an induction chemotherapy were planned for this patient. The patient 
then performed a nasoendoscopy followed by nasopharyngeal CT scan evaluation and showed a good 
response after Chemotherapy. 
Conclusion: Carboplatin and docetaxel chemotherapy management in this patient was given according 
to the management of nasopharyngeal carcinoma and has given a good response to the patient.  
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1. CASE REPORT 
A 57-year-old man was referred to RSUP Dr. Mohammad Hoesin 
Palembang in September 2020. The patient presented with complaints of 
obstruction in both noses (especially in the left nose), headache, nosebleeds, 
headache, runny nose with yellowish white discharge, there is no decrease 
in smelling, and no lumps on both sides of the neck. The patient also 
complained of reduced hearing in the left ear with no history of discharge 
from the ear. The complaints have been felt since 5 months ago. He had a 
previous history of smoking and drinking alcohol.  
On physical examination, the general condition was good. Patient 
was full alert, blood pressure was normal at 120/80 mmHg, pulse was 82 
x/minute, temperature and breathing within normal limits, and there is no 
sign of difficulty in breathing. Neck examination showed no lumps or 
enlarged lymph nodes in both necks. No abnormalities were found on ears 
and throat examination. Furthermore, the patient underwent an anterior 
rhinoscopy, which showed a mass invading both of nasal cavity with lots of 
serous secretion. The mass looked brittle and bleeding easily. We performed 
a tele nasoendoscopy examination, showing a mass in the nasopharynx that 














Picture 1. Nasoendoscopy of the right and left nasopharynx on September 
14th, 2020. 
 
On June 20th, 2020, we performed a radiological CT scan of the 
nasopharynx which showed masses in the right and left nasopharynx, 
obstructing the rosenmuller fossa and pressing the tubarius torus, the mass 
extending to the choana and left nasal cavity, posterolaterally infiltrating the 
parapharyngeal space and left masticator space and destructing the left 
pterygoid plate. The mass also extends superiorly, destructs the walls of the 
left sphenoid and ethmoid sinuses, the left sella dorsum and suspiciously 
extends to the left cavernous sinus. Abdominal ultrasound examination 
showed no visible metastatic nodules. Based on medical history, physical 
examination, and radiology imaging, nasopharyngeal carcinoma was 
obtained. Histopathology results showed a differentiated non keratinizing 
squamous cell carcinoma in the nasopharynx. Patient diagnosed with NPC 
WHO II stage III (T3N0M0) and planned 6 cycles of chemotherapy with 
carboplatin and docetaxel regimen every 3 weeks per cycles, chemotherapy 
starts from October 2020 to February 2021. On February 13th, 2021, during 
his last cycles, his blood result showed that he was anemic (Hb 8.6 gr/dl) 
and leukopenia (WBC 2890 mcl). Patient administered to the hospital and 
we treated the patient with transfusion with 400 cc of PRC and filgrastim 
injection. The patient showed response after the treatment and continued 
with cycle 6th of chemotherapy. The patient showed good condition after 
undergoing chemotherapy and was discharged and prescribed with oral 
medicine for home treatment. The patient has been undergoing six cycle of 
chemotherapy and showed good condition, despite experiences occasional 
nausea and malaise. 
 
 
Picture 2. The axial and coronal plane nasopharyngeal CT scan on June 
20th, 2020 (before chemotherapy). 
 
After the patient had undergone 6 cycles of chemotherapy, the patient 
then returned to the ENT outpatient clinic in Dr. Mohammad Hoesin 
Hospital in February 2021 for follow-up. Patient had no complaints of nasal 
obstruction and nasal bleeding. On physical examination, the patient had no 
mass in both nasal cavities, there also no lumps in both sides of neck. The 
result of nasoendoscopy showed serous secretions in the nasopharynx with 
less masses in the left nasopharyngeal wall.  
 
















Picture 3. Nasoendoscopy of the right and left nasopharynx on February 
23rd, 2021 (post-chemotherapy) 
 
We compared the CT Scan with a contrast of the Nasopharynx result, 
performed on June 20th, 2020, to the CT result, performed on February 23rd, 
2021 the results showed a mass in the left nasopharynx extending into the 
left parapharyngeal space and erosion the left pterygoid plate.  We compared 
with the previous CT Scan, there is no longer any visible expansion of the 












Picture 4. The axial and coronal plane nasopharyngeal CT scan on 
February 23rd, 2021 (after chemotherapy 6th cycles) 
 
2. DISCUSSION 
Nasopharyngeal carcinoma (NPC) is a head and neck malignant tumour 
that occurs from nasopharyngeal epithelial cells. In Indonesia, NPC ranks fifth 
of all malignancies and ranks first in Ear, Nose, Throat, Head and Neck 
Surgery malignancies. The incidence of NPC in Indonesia reaches 6.2 per 
100,000 population per year. Nasopharyngeal carcinoma can occur between 
the ages of 45-54 years. Nasopharyngeal carcinoma occurs more frequently in 
men than women. The clinical symptoms of nasopharyngeal carcinoma are so 
varied that an incorrect diagnosis is often made. The most common symptoms 
are abnormalities of the neck, ears, nose, and cranial nerves [1-3].  
From research data conducted by Masafumi in Japan, for 10 years, NPC 
was found in as many as 620 patients with the most at the age of 60-71 years 
and occurs more frequently in men than women with a ratio of 4.3:1. In a 
study conducted by Kevin, of 101 patients diagnosed with nasopharyngeal 
carcinoma, it was found that there were more men than women with a 
percentage of 70%. Abdul and Salma analyzed some cases of 
nasopharyngeal carcinoma at the Al Nahdha hospital, NPC were found in 
men and women with a ratio of 1.4:1 with a percentage of 21% at the age of 
20-30 years old and 25% at the age of 50-60 years old. At the ENT clinic of 
Mohammad Hoesin Hospital in Palembang from 2017-2018, NPC was 
diagnosed and found in 194 new patients [2, 4-6]. 
The patient was suspected of having nasopharyngeal carcinoma because 
the main complaint was nasal obstruction accompanied by nosebleeds. 
Physical examination found a mass in the nasopharynx. Computed 
tomography with contrast revealed a suspicious impression of 
nasopharyngeal carcinoma with extension to the nasal cavity and paranasal 
sinuses. The clinical symptoms of nasopharyngeal carcinoma can be divided 
into several groups, namely the nasopharynx itself, ear symptoms, eye and 
nerve symptoms, and metastases or symptoms in the neck. Nasopharyngeal 
symptoms can include mild epistaxis or nasal obstruction. Ear disorders are 
an early symptom that arises because the origin of the tumor is close to the 
mouth of the eustachian tube (fossa of rosenmuller). Disorders can include 
tinnitus, fullness and pain in the ear. Endoscopic examination can provide 
information about the location of the tumor on the mucosa but cannot 
determine the internal extent so that in this patient a computed tomography 
scan (CT scan) is performed [2, 7, 8]. 
The patient's nasopharyngeal biopsy revealed undifferentiated 
nasopharyngeal carcinoma. Undifferentiated carcinoma is the most common 
histopathological type of NPC with percentage in endemic areas between 
47% and 92% of all cases in endemic areas. In general, studies from non-
endemic areas have always shown that patients with keratinized carcinoma 
have a worse prognosis than non-keratinized or undifferentiated carcinomas. 
Keratinized squamous cell nasopharyngeal carcinoma has more aggressive 
local tumor growth than non-keratinized and undifferentiated squamous cell 
carcinoma, in which lymphatic and haematogenous spread of metastases is 
more common in this type [9,10].  
CT scan of the patient's nasopharynx showed expansion of the tumor 
into the paranasal sinus and pharyngeal space, but no expansion to the 
cranial or intracranial bases, thus including T3. The patient's lymph nodes 
cervical examination did not find a lump so they were grouped into N0. 
Chest X-ray examination, abdominal ultrasound showed no sign of 
metastasis so that according to the 2018 AJCC classification the patient was 
included in stage III (T3N0M0). The patient is able to do light daily work 
such as homework so that the patient's performance includes ECOG 1.  
The 2021 NCCN guidelines for stage III nasopharyngeal carcinoma 
suggest induction of chemotherapy followed by radiotherapy or concurrent 
chemotherapy with radiotherapy or radiotherapy not followed by 
chemotherapy. For chemotherapy induction, the recommended regimens are 
Gemcitabine or cisplatin, docetaxel or cisplatin or 5-FU. A study compared 
chemoradiotherapy using cisplatin versus carboplatin and showed that the 
3-year life expectancy was the same (78% versus 79%). There is no 
consensus regarding the optimal fractionation of the radiation dose when 
given with concurrent chemotherapy. This patient underwent concurrent 
chemoradiation using carboplatin and docetaxel for 6 cycles [11]. 
After being diagnosed with NPC stage III (T3N0M0), the patient will 
be planned for 6 cycles chemotherapy. This is in accordance with NCCN 
2021 recommendations about NPC management. The induction 
chemotherapy (ICT) preceded with concurrent chemoradiotherapy (CCRT) 
is still controversial and the results are conflicting. Various trials have shown 
that ICT followed by CCRT provides results with a manageable toxicity 
profile and a positive impact on survival [12]. In case of locally advanced 
nasopharyngeal carcinoma (LA-NPC), ICT followed by CCRT can be 
considered as one of the standard treatment options for LA-NPC. In some 
parts of the world LA-NPC is a relatively common disease with a rather 
poor prognosis due to its high metastatic potential. ICT has always been 
controversial. Mane et al found that ICT followed by CCRT compared with 
CCRT alone in LA-NPC gives a clinical improvement that is significant in 
both overall survival and progression‐free survival. A standard option for 
patients with LA-NPC should be considered and ICT was one of them [13]. 
Due to its effectiveness, CCRT followed by adjuvant chemotherapy 
(AC) has been recommended by the National Comprehensive Cancer 
Network (NCCN) as a clinical   standard treatment for LA-NPC [11]. 
However, Chen et al. reported a clinical trial that the additional AC induced 
gastrointestinal toxicities and low patient compliance (63%). ICT is used 
before radiotherapy, it's less toxic, improves tumour shrinkage, and leads to 
early eradication of micrometastases[14]. The 2021 NCCN guidelines 
recommends ICT+CCRT from category III to IIA as one of the most 
appropriate treatments for LA-NPC superior than CCRT (IIB) and 
equivalent to CCRT+AC (IIA) [11].  
In this patient, we selected carboplatin and docetaxel as the 
chemotherapy regimens. Research conducted by Liao et al. (2019) states 
that CCRT with low-dose docetaxel is an effective therapy for locally 
advanced NPC. For patients with low pretreatment EBV DNA levels, 
docetaxel improves a survival benefit mainly by control of regional lymph 
node metastases [15].  
Even though cisplatin has a side effect that can make patients feel 
nausea, vomiting, gives ototoxicity, neurotoxicity and nephrotoxicity, 
cisplatin is still an accepted regimen and there is only 63% and 55% of 
patients completed concurrent and adjuvant chemotherapy. Carboplatin has 
become an interest due to its lower side effects, especially gastrointestinal 
and nephrogenic side effects. Because of the tolerable toxicity of 
carboplatin, patient can be treated as an outpatient. administration, thus 
reducing hospitalization, make it less cost for the treatment and less 
workload for medical personnel. Eisenberger implied that when given 
concurrently with radiation in locally advanced head and neck cancers, 100 
mg/m2/week of carboplatin was well tolerated [16]. 
Chitaparanux et al. found that carboplatin based regimen is better in 
tolerability compared to the cisplatin regimen. Moreover, the treatment 
efficacy of carboplatin is not different from the standard regimen in the 







treatment of locoregional advanced stage NPC [16]. The cisplatin group is 
more toxic for renal, has a side effect of leukopenia and anemia, but in the 
carboplatin group, it's more in thrombocytopenia as a side effect. The 3-year 
disease free survival rates were higher for the cisplatin group than the 
carboplatin group. The 3-year overall survival rates were 77.7% for cisplatin 
group and 79.2% for carboplatin groups. Carboplatin showed similar 
efficacy with cisplatin and have a better tolerability and could be used as an 
alternative regimen [17]. 
From this case, the results of nasopharyngeal CT scan after 
chemoradiotherapy revealed mass in the left nasopharynx extending into the 
left parapharyngeal space and erosion of the left pterygoid plate. Compared to 
the CT scan on June 20th, 2020, there is no longer any visible expansion of the 
mass to the left nasal cavity, left masticator space, left sphenoidalis and left 
ethmoidalis. The patient experiences a good response. Assessment of the 
results of treatment with chemotherapy, either alone or in combination with 
surgery or radiotherapy, is usually done after 3-4 weeks. Complete response is 
said when all tumors disappear for a period of at least 4 weeks. Head and neck 
CT scan are diagnostic modalities for follow-up after NPC therapy. The 
sensitivity and specificity of CT scan after treatment were 67% and 32%. 
Imaging to assess recurrence is performed in between 6 months [12]. 
 
 
Picture 5. NCCN Guidelines Version 1.2021 Cancer of the Nasopharynx [11]. 
3. CONCLUSION 
Chemotherapy management in this patient is similar to the 
management of nasopharyngeal carcinoma and has given a good response 
to the patient. One of the standard treatment options for LA-NPC is to add 
IC to CCRT for NPC therapy. Carboplatin and docetaxel could be used as 
an alternative regimen and showed a similar efficacy with other 
chemotherapy regimens and have a better tolerability. 
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